BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nozaki A, Chuma M, Hara K, Moriya S, Fukuda H, Numata K, Tanaka K, Morimoto M, Sakamaki K, Yamanaka T, Kondo M, Maeda S. Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: A prospective observational study. Medicine (Baltimore) 2021;100:e25110. [PMID: 33761674 DOI: 10.1097/MD.0000000000025110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Tangvoraphonkchai K, Suttichaimongkol T, Kularbkaew C, Sangaimwibool P, Sukeepaisarnjaroen W. Application of Mac-2 binding protein glycosylation isomer as a non-invasive biomarker for probing liver disease. Sci Rep 2022;12:6757. [PMID: 35474106 DOI: 10.1038/s41598-022-10744-5] [Reference Citation Analysis]
2 Smirne C, D'Avolio A, Bellan M, Gualerzi A, Crobu MG, Pirisi M. Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose. Pharmacol Res Perspect 2021;9:e00811. [PMID: 34152088 DOI: 10.1002/prp2.811] [Reference Citation Analysis]
3 Ramos-Rincon JM, Pinargote-Celorio H, de Mendoza C, Ramos-Belinchón C, Barreiro P, Treviño A, Corral O, Soriano V. Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain. Hepatol Int 2022. [PMID: 35666390 DOI: 10.1007/s12072-022-10365-0] [Reference Citation Analysis]